Life Sciences

  • September 23, 2026

    Motley Rice Partner Tapped For Opioid Case Co-Lead Counsel

    The Ohio federal judge overseeing multidistrict opioid litigation appointed on Wednesday Donald Migliori, a managing partner at Motley Rice LLC, as co-lead counsel in the wake of the death of the firm's co-founder Joe Rice, who had served in the position for the past eight years.

  • September 23, 2026

    Vividion Investor Wants IP Suit Over $2B Bayer Deal Revived

    CHP III LP urged the Delaware Supreme Court on Wednesday to revive its suit over allegedly diverted intellectual property in Vividion Therapeutics Inc.'s $2 billion sale to Bayer Corp., while the defendants argued the investor is trying to turn a corporate injury into a direct stockholder claim that did not survive the merger.

  • September 23, 2026

    Legal Groups Back Firm In NC High Court Malpractice Appeal

    Legal advocacy groups are standing behind the law firm Hedrick Gardner Kincheloe & Garofalo LLP in asking North Carolina's highest court to find that the state's four-year statute of repose on legal malpractice claims creates an immovable end-date to liability.

  • September 23, 2026

    Chinese Medicinal Chemical Exporter Faces Triple-Digit Duty

    A pharmaceutical compound imported from China has been found to have been subsidized, and at least one exporter of the goods in question could face triple-digit retroactive countervailing duties, according to a notice issued Wednesday by the U.S. Department of Commerce.

  • September 23, 2026

    DOJ Pressed On Gender Care Ban In Federal HIV Program

    A Massachusetts federal judge on Wednesday skeptically questioned the Trump administration's authority to prohibit doctors from providing gender-affirming care as part of a longstanding, federally funded HIV program.

  • September 22, 2026

    UMass Hospital Co. Beats Ex-VP's COVID Vaccine Firing Claim

    A jury cleared a central Massachusetts hospital system of liability for terminating a compliance officer who refused a COVID-19 shot, finding Tuesday she failed to show a sincere religious belief against vaccination.

  • September 22, 2026

    CVS Beats Malpractice Suit Over Pharmacy Mix-Up

    A California appeals court on Tuesday upheld the dismissal of a suit accusing a CVS pharmacy of negligently giving the wrong prescription medication to a woman, which allegedly caused years of seizures, citing flawed expert testimony from plaintiff's expert.

  • September 22, 2026

    FDA Must Revisit MiMedx Wound Care Powder Classification

    A Georgia federal judge vacated the Food and Drug Administration's classification of biomedical company MiMedx's wound care treatment as a biological product, which carries heightened regulatory requirements, finding the agency's determination was arbitrary because it had classified similar products as devices.

  • September 22, 2026

    Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win

    Yale University and Biohaven Therapeutics Ltd. have requested attorney fees topping $23.1 million, plus $2 million each in exemplary damages, after winning a $4 million trial verdict, though both entities are also seeking a new trial to readdress damages on trade secrets and contract breach claims.

  • September 22, 2026

    Commerce Sets Zero-Tariff Rules For Specialty Drugs

    Nuclear medicine and animal healthcare drugs are some of the products that will qualify for a zero rate when tariffs on imported pharmaceuticals take effect at the end of the month, according to a notice issued by the U.S. Department of Commerce's Bureau of Industry and Security.

  • September 22, 2026

    8th Circ. Questions Iowa's Bid To Unblock Parts Of PBM Law

    The Eighth Circuit on Tuesday appeared skeptical of the state of Iowa's bid to have the appellate court unblock parts of its law limiting pharmacy benefit managers' power to set drug prices, with multiple judges questioning different aspects of the state's standing and federal preemption analysis.

  • September 21, 2026

    Moderna Says Sanofi Wants To 'Unjustly Profit' In Vax IP Suit

    Sanofi's patent infringement suit against Moderna is an attempt to "unjustly profit" from the latter's COVID-19 vaccines after Sanofi was unable to produce its own, Moderna has told a New Jersey federal court.

  • September 21, 2026

    Ex-PetIQ CEO's Brother Admits To Illicit Trades Over Deal Info

    An Idaho man pled guilty Monday in federal court to trading on confidential information he received from his brother, the former CEO of PetIQ, about the company's acquisition by Bansk Group in August 2024.

  • September 21, 2026

    Telix Pharma Bets Up To $2.3B For ITM In Radiopharma Push

    Telix Pharmaceuticals Ltd. on Monday unveiled plans to acquire ITM Isotope Technologies Munich SE in a deal worth up to $2.3 billion that was built by three law firms.

  • September 21, 2026

    Ex-NFL Player Gets New Trial In $328M Medicare Fraud Case

    A Texas federal judge has granted a new trial for a former NFL player convicted in a $328 million Medicare billing scheme, finding that the government presented unreliable testimony and did not identify the alleged lies the defendant used to influence physicians.

  • September 21, 2026

    Medical Orgs Target Rule On Medicaid Work 'Frailty' Exclusion

    Federal regulation implementing a statutory "medical frailty" exclusion from Medicaid work requirements violates the Administrative Procedure Act, burdens healthcare providers and threatens to cause millions of people to lose their coverage, medical groups told a Maryland federal court in a complaint.

  • September 21, 2026

    Regeneron Investors Can't Use FCA Action To Support Suit

    Regeneron Pharmaceuticals Inc. and its executives have beaten a proposed class action accusing them of misleading investors about the company's revenue prospects for its vision loss drug and inflating reimbursements, with a judge ruling that the suit does not use the U.S. Department of Justice's False Claims Act suit against the company to plead share losses.

  • September 21, 2026

    Smart-Ring Maker Oura Launches $2.1B IPO Plan

    Fitness-tracking ring maker Oura on Monday unveiled a target price range for its public debut, telling the U.S. Securities and Exchange Commission that it plans to raise roughly $2.1 billion.

  • September 21, 2026

    Varian, Gov't Appeal Foreign Dividend Decision To 9th Circ.

    Varian Medical Systems Inc. is appealing a U.S. Tax Court decision that it owes more than $7.2 million to the Internal Revenue Service as a result of the court limiting its deemed dividends deduction, while the government is also appealing, according to filings in the Ninth Circuit.

  • September 21, 2026

    Sidley Lands Life Sciences Pair From King & Spalding

    Sidley Austin LLP announced Monday that it has brought on two attorneys from King & Spalding LLP to bolster its capacity to handle life sciences-related litigation and regulatory matters involving the U.S. Food and Drug Administration.

  • September 21, 2026

    Judge OKs Up To $3.2M In BioXcel Employee Ch. 11 Bonuses

    A Delaware bankruptcy judge approved employee retention and executive incentive payments that could total up to $3.2 million as AI-bolstered pharmaceutical group BioXcel works to sell its assets in Chapter 11.

  • September 18, 2026

    Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End

    Eli Lilly & Co. turned Nektar Therapeutics' autoimmune-disease drug Rezpeg into "damaged goods" by breaching the companies' co-development deal and delaying the medication's development in favor of a competing drug the pharma giant subsequently acquired, Nektar's counsel told a California federal jury during closing arguments Friday in the $1 billion case.

  • September 18, 2026

    Colo. Judge Mulls Sanction For Hospital In Gender Care Suit

    Transgender adolescent patients of Children's Hospital Colorado told a state judge the court must sanction the hospital for refusing to resume providing gender-affirming medical care for transgender youth patients, saying Friday that "nothing has changed" since the patients filed their January lawsuit.

  • September 18, 2026

    Texas Pregnancy Center Shutters To End Birth Tourism Suit

    A Texas-based pregnancy center on Friday agreed to shut down to resolve allegations by state Attorney General Ken Paxton that it helped Chinese nationals give birth in the U.S. while on tourist visas so their children could obtain birthright citizenship.

  • September 18, 2026

    Abbott's Spine Implants Cause Nerve Damage, Suit Claims

    A Pennsylvania woman is suing Abbott Laboratories and one of its subsidiaries in federal court, alleging she suffered permanent nerve damage as a result of a faulty spine implant and Abbott's representatives discouraging her from getting it removed.

Expert Analysis

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

  • Series

    Law School's Missed Lessons: Surviving A Long Trial

    Author Photo

    Most of law school trial advocacy is geared toward the sprint of trying a short case, but beyond managing a cross-examination or closing argument, effectively handling the marathon of a lengthy trial requires the ability to maintain composure, organization and credibility with the jury, says Mihir Elchuri at Hirschler.

  • AI Chatbot's Medical Claims Highlight Enforcement Risks

    Author Photo

    The Pennsylvania State Board of Medicine's recent lawsuit against Character Technologies, arguing that an artificial intelligence chatbot engaged in the unlicensed practice of medicine, may provide other state licensing boards with a road map for going after AI platforms, and counsel should advise clients to calibrate compliance accordingly, say attorneys at Cooley.

  • 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers

    Author Photo

    The recent Seventh Circuit holding in Steidinger v. Blackstone Medical Services that unwanted marketing text messages are not telephone calls under the Telephone Consumer Protection Act may strengthen companies' responses to presuit demand letters and early-stage litigation claims premised on do-not-call text theories, say attorneys at Holland & Knight.

  • How Calif. Ruling Defines Drug Cos.' R&D Responsibilities

    Author Photo

    The California Supreme Court's recent ruling in the Gilead Tenofovir Cases, which held that drugmakers have no duty to bring allegedly safer alternatives to market more quickly, is a win for pharmaceutical companies — but not a grant of blanket immunity for all early-stage drug development decisions, say attorneys at King & Spalding.

  • Midyear Trends, Takeaways As Securities Class Actions Surge

    Author Photo

    High numbers of securities class actions through June suggest filings will stay elevated, with factors like changing enforcement attitudes, media scrutiny and the proliferation of potential defendants serving as both cause and effect in increased litigation involving AI-related disclosures, health and tech companies, and foreign issuers, say attorneys at Alston & Bird.

  • Series

    Going To Hardcore Shows Makes Me A Better Lawyer

    Author Photo

    While government contracts law and the hardcore scene may seem entirely unrelated, in my experience, both are about community, focus, being prepared for the unexpected and managing chaos, says Isaac Natter at Fluet.

  • How Home Infusion Providers Can Adapt To Enrollment Pause

    Author Photo

    Recent Centers for Medicare & Medicaid Services moratoria on new enrollments of home health agencies, medical equipment companies and hospices make home infusion providers' compliance obligations more complex and ambiguous, requiring new careful consideration of specific enrollment requirements and limitations, say attorneys at Quarles & Brady.

  • USPTO Practitioner Roster Reflects A More Veteran Workforce

    Author Photo

    An analysis of the U.S. Patent and Trademark Office's Office of Enrollment and Discipline practitioner roster reveals a widening demographic imbalance between new practitioners and those with more experience, but despite this trend, an expected falloff in practitioner numbers has yet to arrive, says Ian Schick at Paximal.

  • How 'Markedly Different' Test Shapes Patent Eligibility Debate

    Author Photo

    Following last month's U.S. Senate hearing on the proposed Patent Eligibility Restoration Act, it is important to examine how courts and the U.S. Patent and Trademark Office have applied the 46-year-old "markedly different characteristics" framework to determine eligibility of composition-of-matter claims, say attorneys at WilmerHale.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.